TransCode Therapeutics has reported positive findings with its primary treatment candidate, TTX-MC138, in mouse models with human glioblastoma multiforme tumors.

NMD Pharma A/S has revealed that the initial patient has received their first dose in a Phase II clinical study of the ClC-1 inhibitor NMD670 in individuals affected by spinal muscular atrophy.

Sandoz gains consent from the European Commission for its unique multiple sclerosis biosimilar, Tyruko® (natalizumab) in Europe.

Lantern Pharma Inc. has started Phase 1 clinical trial on its experimental drug, LP-184, for advanced solid tumors. This is part of the company's ongoing clinical drug development.

Escient Pharmaceuticals commences trial-based study of EP262, an innovative, orally-taken MRGPRX2 blocker for chronic inducible hives.

Data provided by Longhorn vaccine and diagnostics indicate that lhnvd-201 has neutralizing activity against covid-19 and influenza coinfection.

Appili Therapeutics a biodefense and infectious disease drug company, announced that its production and marketing partner, Saptalis Pharmaceuticals, received US FDA approval for Metronidazole Oral Suspension 500mg/5mL.

Nova Therapeutics, a biotech firm specializing in Influenza A treatments, received US FDA approval for its IND application for influenza A suppressant, VNT-101.

Merck reported that the phase III KEYNOTE-A39/EV-302 test halted disease progression in certain patients with local or metastatic urothelial cancer who hadn't received prior treatment.

Genmab Unveils EU Commission's Authorization for TEPKINLY® (epcoritamab) to Treat Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) in Adults.

Lutathera®, a radioligand therapy by Novartis, showed significant progression-free survival rates in initial stage advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Shanghai Henlius Biotech, Inc. has made a public announcement that the NMPA has given approval to the NDA for an innovative fresh indication of HANSIZHUANG (serplulimab injection).